Morningstar

H. Lundbeck AS Ordinary Shares - Class B HLUN B

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 44.24 +0.04 (0.09%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Lundbeck Earnings: Strong Uptake of Strategic Brands Drives Sales, Helps Offset Generic Erosion

Rachel Elfman

Lundbeck reported solid half-yearly results, highlighted by total revenue of DKK 10.74 billion, representing 10% growth from the prior-year period. Robust performance from Lundbeck’s strategic brands (Vyepti, Rexulti, Abilify Maintena, and Trintellix) accounted for 73% of total revenue and grew 19% compared with the first half of 2024. Investors reacted favorably, sending the stock up 4%. Lundbeck is tracking our expectations, and we maintain our fair value estimate of DKK 42.50 per share. We view the stock as fairly valued, currently trading in 3-star territory.

Read Full Report

Price vs Fair Value

View History
HLUN B is trading at a 535% premium.
Price
DKK 44.24
Fair Value
DKK 75.80
Uncertainty
High
1-Star Price
DKK 88.59
5-Star Price
DKK 83.90
Economic Moat
Jplv
Capital Allocation
Cllzfdkhm

Bulls Say, Bears Say

Bulls

Vyepti received FDA approval in 2020 and has already been launched in 24 markets globally.

Bears

Due to the complex nature of CNS disorders and the high frequency of placebo responses, which can confound trial results, the development process has been filled with obstacles.

Show More

Trading Information

Previous Close Price
DKK 44.20
Day Range
DKK 43.94–44.60
52-Week Range
DKK 31.62–48.50
Bid/Ask
DKK 44.14 / DKK 44.22
Market Cap
DKK 43.89 Bil
Volume/Avg
400,282 / 557,245

Key Statistics

Price/Earnings (Normalized)
8.84
Price/Sales
2.12
Dividend Yield (Trailing)
1.58%
Dividend Yield (Forward)
1.58%
Total Yield
1.68%

Company Profile

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
5,800
Website
https://www.lundbeck.com

Competitors

Valuation

View More
Metric
HLUN B
ALNY
EXEL
Price/Earnings (Normalized)
 8.84155.8517.20
Price/Book Value
 1.89—3.53
Price/Sales
 2.1214.754.01
Price/Cash Flow
 8.3967.7316.42
Price/Earnings
HLUN B
ALNY
EXEL

Financial Strength

Metric
HLUN B
ALNY
EXEL
Quick Ratio
 1.322.784.05
Current Ratio
 1.883.014.27
Interest Coverage
 —−0.35—
Quick Ratio
HLUN B
ALNY
EXEL

Profitability

Metric
HLUN B
ALNY
EXEL
Return on Assets (Normalized)
 11.51%5.94%14.82%
Return on Equity (Normalized)
 19.52%—19.05%
Return on Invested Capital (Normalized)
 15.80%21.50%14.99%
Return on Assets
HLUN B
ALNY
EXEL

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
GrfvcpyxhnKbr$88.3 Bil
 Merck KGaA ADR
MKKGY
CjwrfwzwbsQlzzfv$77.4 Bil
 Haleon PLC ADR
HLN
GsdbhptfVzg$47.3 Bil
 Teva Pharmaceutical Industries Ltd ADR
TEVA
LkmmcgdjYdjz$19.0 Bil
 Viatris Inc
VTRS
QnrprlrkRcsb$13.9 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
RwzzrtpkDglrq$13.4 Bil
 Catalent Inc
CTLT
PxpdbbsjWdzyjq$10.9 Bil
 Prestige Consumer Healthcare Inc
PBH
FbdpmqhdXyvhz$3.5 Bil
 Perrigo Co PLC
PRGO
RvjqsqpbVfv$3.5 Bil
 Green Thumb Industries Inc
GTBIF
JgrcwdhrMvvt$2.5 Bil

Sponsor Center